Observational studyThe Lancet. Public health2019
The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study.
Observational study in The Lancet. Public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- All-Cause and Cause-Specific Mortality Among People Using Extramedical Opioids: A Systematic Review and Meta-analysis.JAMA psychiatry · 2020Pooled it
- Patient Satisfaction With Standard Methadone and Flexible Buprenorphine/Naloxone Models of Care: Results From a Pragmatic Randomized Controlled Clinical Trial.Journal of addiction medicineTrial
- Factors Associated With Opioid Agonist Treatment Engagement and Harm Reduction Service Use: Findings From the New South Wales Opioid Dependence Survey.Drug and alcohol review · 2026Article
- Trauma-informed psychological support alongside long-acting injectable buprenorphine: clients' perspectives on the Buvidal psychological support service (BPSS) pilot in Wales.Frontiers in psychiatry · 2026Article
- Injectable buprenorphine during transition out of prison: A pilot partially randomized preference trial protocol.Contemporary clinical trials · 2025Article
- The effect of take-home naloxone kits on opioid-related deaths in Alberta, Canada: An ecological analysis.Canadian journal of public health = Revue canadienne de sante publique · 2025Article
- Disparities in Opioid Agonist Treatment Accessibility for Priority Populations in New South Wales, Australia.Drug and alcohol review · 2025Article
- Provider costs of treating opioid dependence with extended-release buprenorphine in Australia.Drug and alcohol review · 2025Article
- Quality of Sleep and Related Factors in Individuals Undergoing Methadone Maintenance Treatment.Addiction & health · 2025Article
- Treatment utilization among people with drug use disorders in prison: a national longitudinal cohort study.Health & justice · 2024Article
- Characterizing people who inject drugs with no history of opioid agonist therapy uptake in Iran: Results from a national bio-behavioural surveillance survey in 2020.International journal of mental health and addiction · 2024Article
- CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers.Journal of virus eradication · 2023Article
- Article
- Incidence of suicide and self-harm among people with opioid use disorder and the impact of opioid agonist treatment: A retrospective data linkage study.Drug and alcohol dependence · 2023Article
- History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder.Drug and alcohol dependence reports · 2023Review
- Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada.International journal of qualitative studies on health and well-being · 2022Article
- Barriers and facilitators to opioid agonist therapy in rural and remote communities in Canada: an integrative review.Substance abuse treatment, prevention, and policy · 2022Review
- Opioid agonist treatment take-home doses ('carries'): Are current guidelines resulting in low treatment coverage among high-risk populations in Canada and the USA?Harm reduction journal · 2022Review
- Data Resource Profile: The Opioid Agonist Treatment and Safety (OATS) Study, New South Wales, Australia.International journal of epidemiology · 2021Article
- Individual and structural correlates of willingness for intravenous buprenorphine treatment among people who inject sublingual buprenorphine in France.Harm reduction journal · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
backgroundEvidence on the effectiveness of opioid agonist treatment (OAT) in reducing crime is mixed. We aimed to assess the effect of OAT on crime in terms of delaying time to first charge and reducing overall charge rates, as well as the relationship between OAT retention and overall charge rates.
methodsWe did a retrospective cohort study of opioid-dependent people who entered OAT for the first time between Jan 1, 2004, and Dec 30, 2010, in New South Wales (NSW), Australia. We used three linked NSW and national administrative datasets. Data on OAT were obtained from the Pharmaceutical Drugs of Addiction System, data on charges were obtained from the Reoffending Database, and data on mortality were obtained from the National Death Index. The cohort was followed up until Dec 31, 2011. Time-dependent OAT exposure was modelled using Cox proportional hazards models (time to first charge) and Andersen-Gill intensity models (total charge-days). Retention in OAT was modelled using two features of treatment engagement, number of OAT episodes and proportion of follow-up time in OAT (presented in quartile groupings: lowest, low-mid, low-high, highest) using zero-inflated negative binomial regression (total charges). All models were adjusted for sociodemographic, criminographic, and treatment-related variables.
findings10 744 new OAT entrants were included in the study. 5751 (53·5%) people were charged with an offence. In adjusted analyses, OAT was associated with an initial benefit in delaying the time to first charge (hazard ratio 0·43, 95% CI 0·33-0·55) and reducing total charge-days (0·39, 95% CI 0·30-0·52); however, these protective effects reduced over time. Total charge rates were higher as the number of OAT episodes increased (incident rate ratio [IRR] 1·13, 95% CI 1·11-1·15), and when relatively lower proportions of time were spent in OAT (IRR among the lowest three quartiles ranged from 1·11 [95% CI 1·02-1·21] to 1·22 [95% CI 1·12-1·33]).
interpretationOAT was associated with a reduction in overall charge rates and was more protective as treatment engagement increased. Maximising treatment retention is crucial to achieving long-term health and social benefits of OAT.
fundingAustralian National Health and Medical Research Council, Australian Institute of Criminology, National Institute on Drug Abuse, Australian Government Department of Health, UNSW Sydney.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.